arsenic trioxide

(redirected from Trisenox)
Also found in: Dictionary, Thesaurus, Medical.

arsenic trioxide

[′ärs·ən·ik ‚tri′äk‚sīd]
(inorganic chemistry)
As2O3 A toxic compound, slightly soluble in water; octahedral crystals change to the monoclinic form by heating at 200°C; occurs naturally as arsenolite and claudetite; used in small quantities in some medicinal preparations. Also known as arsenic oxide; arsenious acid.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic leukemia.
Trisenox is a registered trademark of Teva Pharmaceutical Industries Ltd.
Biopharmaceutical company CTI BioPharma Corp (Nasdaq:CTIC)(MTA:CTIC) reported on Thursday the receipt of USD10m in milestone payment related to the achievement of sales milestones for TRISENOX (arsenic trioxide).
related to the achievement of a milestone for US Food and Drug Administration approval of Trisenox (arsenic trioxide) for first line treatment of acute promyelocytic leukemia, the company said.
CTI BioPharma (Nasdaq:CTIC)(MTA:CTIC) reported on Monday that it has received a USD10m milestone payment from Teva Pharmaceutical Industries related to the achievement of sales milestones for TRISENOX (arsenic trioxide).
"Establishing a commercial presence in Europe is part of Cell Therapeutics' strategic plan to expand the clinical development and sales of TRISENOX," stated James A.
M2 EQUITYBITES-December 4, 2014-CTI BioPharma awarded USD15m milestone payment for TRISENOX
M2 PHARMA-December 4, 2014-CTI BioPharma awarded USD15m milestone payment for TRISENOX
M2 EQUITYBITES-December 2, 2013-Cell Therapeutics Inc wins USD5m milestone payment for TRISENOX
M2 PHARMA-December 2, 2013-Cell Therapeutics Inc wins USD5m milestone payment for TRISENOX